Second interim analysis of RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.6081
Abstract: 6081Background: Sorafenib and lenvatinib are oral MKIs approved for the treatment of RAI-R DTC; however, there is no consensus on when patients with asymptomatic RAI-R DTC should start treatment wi... read more here.
Keywords: patients asymptomatic; treatment; interim analysis; second interim ... See more keywords